ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING. Mediterr J Hematol Infect Dis [Internet]. 2018 Feb. 15 [cited 2026 May 2];10(1):e2018014. Available from: https://www.mjhid.org/mjhid/article/view/2018.014